$6.37
-0.11 (-1.70%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RXST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 1 observational · 8 with posted results
Held by 13 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, +8 more) · FINRA short interest 4.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment StudyNCT07347379observationalMean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit | — | Enrolling by invitation | Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD) | Aphakia Cataract | 108 | Sep 2026 | ≤ 42 d | 2026-08-12 |
| RxSight Light Adjustable Lens and Light Delivery Device New Enrollment StudyNCT05202808results2025-04-20Absolute Manifest Refraction Spherical Equivalent (MRSE) Compared Between the Two Study Groups, LAL and ControlRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD), Control IOL | Aphakia, Cataract | 500 | 2024-09-11actual | — | 2025-04-20 |
| Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual OutcomesNCT04529616results2025-02-10Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or BetterOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD) | Aphakia, Cataract | 79 | 2022-10-01actual | — | 2025-02-10 |
| A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of FocusNCT04177771results2025-01-07Monocular Depth of Focus (DOF) Measured at the logMAR 0.2 Level Compared Between LAL Treatment Group and Control GroupRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: Technology changes. | Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD) - Pre-COVID Population, SofPort LI61AO IOL, Tecnis ZCB00 or ZTC150 IOL | Aphakia, Cataract, Presbyopia | 34 | 2021-12-20actual | — | 2025-01-07 |
| Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive SurgeryNCT03660865results2021-11-22Magnitude of Manifest Cylinder (MRCYL) Compared Between the Two Study Groups, LAL and ControlRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD), Control IOL | Aphakia, Cataract | 105 | 2020-04-01actual | — | 2021-12-23 |
| Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual OutcomesNCT03895034results2021-09-22Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or BetterOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD) | Aphakia, Cataract | 66 | 2020-03-01actual | — | 2022-05-12 |
| A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)NCT04005586results2021-06-11Mean Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control GroupsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Light Delivery Device (LDD) | Aphakia, Cataract | 25 | 2020-03-01actual | — | 2021-06-11 |
| Clinical Study to Evaluate the RxSight Light Adjustable Lens With the Light Delivery Device in Subjects With Preoperative Corneal AstigmatismNCT03771352results2021-05-25Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or BetterOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan: CSP-025-05 rev DE protocol and SAP 05-16-2019_Redacted ↗ · Study Protocol and Statistical Analysis Plan: CSP-025 rev 5 UK protocol and SAP 05-16-2019_Redacted ↗ | Not applicable | Completed | Device: RxSight RxLAL | Cataract | 55 | 2019-07-01actual | — | 2021-06-09 |
| Exploratory Study to Evaluate Uncorrected Distance Vision and Quality of Vision After Light Treatments of an Implanted RxSight Light Adjustable Lens (RXLAL) With The Light Delivery Device (LDD) in Subjects With Preoperative Corneal AstigmatismNCT03729024results2021-05-19Percent of Eyes With UCDVA of 20/20 or BetterOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD) | Aphakia, Cataract | 21 | 2019-04-15actual | — | 2021-08-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19